Page last updated: 2024-08-26

bosentan anhydrous and Arteriosclerosis

bosentan anhydrous has been researched along with Arteriosclerosis in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bröijersén, A; Bulhak, A; Gonon, AT; Pernow, J	1
Hirata, Y; Kanno, K	1
Ferdinand, KC	1
Badiwala, MV; Dhillon, B; Fedak, PW; Li, RK; Li, SH; Mickle, DA; Verma, S; Weisel, RD	1

Reviews

2 review(s) available for bosentan anhydrous and Arteriosclerosis

Article	Year
[Endothelin]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 8 Topics: Animals; Arteriosclerosis; Biomarkers; Bosentan; Diagnostic Techniques, Endocrine; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Receptors, Endothelin; Reference Values; Sulfonamides	2005
Update in pharmacologic treatment of hypertension. Cardiology clinics, 2001, Volume: 19, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteriosclerosis; Bosentan; Bradykinin; Calcium Channel Blockers; Diabetes Complications; Diuretics; Drug Therapy, Combination; Endothelin-1; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Pyridines; Quality of Life; Renal Insufficiency; Renin-Angiotensin System; Risk Factors; Sulfonamides; Systole; Thiazepines; Treatment Outcome	2001

Article

Year

[Endothelin].

Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 8

Topics: Animals; Arteriosclerosis; Biomarkers; Bosentan; Diagnostic Techniques, Endocrine; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Receptors, Endothelin; Reference Values; Sulfonamides

2005

Update in pharmacologic treatment of hypertension.

Cardiology clinics, 2001, Volume: 19, Issue:2

Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteriosclerosis; Bosentan; Bradykinin; Calcium Channel Blockers; Diabetes Complications; Diuretics; Drug Therapy, Combination; Endothelin-1; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Pyridines; Quality of Life; Renal Insufficiency; Renin-Angiotensin System; Risk Factors; Sulfonamides; Systole; Thiazepines; Treatment Outcome

2001

Other Studies

2 other study(ies) available for bosentan anhydrous and Arteriosclerosis

Article	Year
Cardioprotective effect of an endothelin receptor antagonist during ischaemia/reperfusion in the severely atherosclerotic mouse heart. British journal of pharmacology, 2005, Volume: 144, Issue:6 Topics: Animals; Arteriosclerosis; Bosentan; Cardiotonic Agents; Coronary Circulation; Endothelin Receptor Antagonists; Fibrosis; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase; Reperfusion; Sulfonamides	2005
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002, Apr-23, Volume: 105, Issue:16 Topics: Antibodies; Arteriosclerosis; Biomarkers; Bosentan; C-Reactive Protein; Cell Adhesion Molecules; Cells, Cultured; Chemokine CCL2; Endothelin-1; Endothelium, Vascular; Humans; Inflammation; Interleukin-6; Lipoproteins, LDL; Macrophages; Models, Cardiovascular; Sulfonamides	2002

Article

Year

Cardioprotective effect of an endothelin receptor antagonist during ischaemia/reperfusion in the severely atherosclerotic mouse heart.

British journal of pharmacology, 2005, Volume: 144, Issue:6

Topics: Animals; Arteriosclerosis; Bosentan; Cardiotonic Agents; Coronary Circulation; Endothelin Receptor Antagonists; Fibrosis; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase; Reperfusion; Sulfonamides

2005

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein.

Circulation, 2002, Apr-23, Volume: 105, Issue:16

Topics: Antibodies; Arteriosclerosis; Biomarkers; Bosentan; C-Reactive Protein; Cell Adhesion Molecules; Cells, Cultured; Chemokine CCL2; Endothelin-1; Endothelium, Vascular; Humans; Inflammation; Interleukin-6; Lipoproteins, LDL; Macrophages; Models, Cardiovascular; Sulfonamides

2002